GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celcuity Inc (NAS:CELC) » Definitions » PB Ratio

Celcuity (Celcuity) PB Ratio : 3.60 (As of May. 26, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Celcuity PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-26), Celcuity's share price is $15.64. Celcuity's Book Value per Share for the quarter that ended in Mar. 2024 was $4.35. Hence, Celcuity's PB Ratio of today is 3.60.

The historical rank and industry rank for Celcuity's PB Ratio or its related term are showing as below:

CELC' s PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 25.4
Current: 3.6

During the past 9 years, Celcuity's highest PB Ratio was 25.40. The lowest was 0.00. And the median was 0.00.

CELC's PB Ratio is ranked worse than
65.09% of 1312 companies
in the Biotechnology industry
Industry Median: 2.5 vs CELC: 3.60

During the past 12 months, Celcuity's average Book Value Per Share Growth Rate was -22.60% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 69.00% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 29.00% per year.

During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Celcuity was 69.00% per year. The lowest was -28.50% per year. And the median was 38.70% per year.

Back to Basics: PB Ratio


Celcuity PB Ratio Historical Data

The historical data trend for Celcuity's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celcuity PB Ratio Chart

Celcuity Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only 5.65 8.06 2.86 2.27 2.66

Celcuity Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.83 2.20 2.20 2.66 4.97

Competitive Comparison of Celcuity's PB Ratio

For the Biotechnology subindustry, Celcuity's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Celcuity's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celcuity's PB Ratio distribution charts can be found below:

* The bar in red indicates where Celcuity's PB Ratio falls into.



Celcuity PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Celcuity's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2024)
=15.64/4.346
=3.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Celcuity  (NAS:CELC) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Celcuity PB Ratio Related Terms

Thank you for viewing the detailed overview of Celcuity's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Celcuity (Celcuity) Business Description

Traded in Other Exchanges
N/A
Address
16305 36th Avenue North, Suite 100, Minneapolis, MN, USA, 55446
Celcuity Inc is a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications. The company's therapeutic candidate is gedatolisib, a potent, well-tolerated, small molecule dual inhibitor, administered intravenously, that selectively targets all Class I isoforms of PI3K and the mammalian target of rapamycin (mTOR).
Executives
Richard E Buller director C/O CELCUITY INC., 16305 36TH AVE. N., #100, MINNEAPOLIS MN 55446
David Dalvey director C/O BLUE ROCK ADVISORS, INC., 80 SOUTH EIGHTH STREET SUITE 3915, MINNEAPOLIS MN 55402
Leo Furcht director C/O CELCUITY, 16305 36TH AVENUE N., #100, MINNEAPOLIS MN 55445
Brian F Sullivan director, 10 percent owner, officer: Chief Executive Officer 16305 36TH AVENUE N, MINNEAPOLIS MN 55446
Polly A. Murphy director C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Richard Nigon director CEDAR POINT CAPITAL, 150 SOUTH 5TH STREET, MINNEAPOLIS MN 55402
Lance G. Laing director, 10 percent owner, officer: Chief Science Officer, VP C/O CELCUITY, 16305 36TH AVENUE N., #450, MINNEAPOLIS MN 55446
Vicky Hahne officer: Chief Financial Officer C/O CELCUITY, 16305 36TH AVENUE N., #450, MINNEAPOLIS MN 55446
Maureen Therese Cronin director C/O CELCUITY, 16305 36TH AVENUE N., #450, MINNEAPOLIS MN 55446